Abstract 1397P
Background
Antibody-drug conjugates (ADCs) may extend targeted therapy to patients (pts) whose tumors express an antigen regardless of the presence of a driver mutation. Telisotuzumab vedotin (ABBV-399), a first-in-class MET (or c-Met)-directed ADC, had promising monotherapy anticancer activity in previously treated pts with MET-overexpressing (OE), non-squamous EGFR wild type NSCLC (Camidge et al. JCO. 2022;40:16 suppl, 9016). Characterization of MET OE NSCLC, a novel biomarker-defined therapeutically relevant subgroup, is thus warranted. MET OE was evaluated in a real-world cohort and co-associated with mRNA expression, MET gene amplification (METamp) and mutations, and outcomes to understand prognosis of MET OE NSCLC.
Methods
The cohort comprised treated pts with stage IV NSCLC seeking care at City of Hope National Medical Center in ≥2016 and had tissue adequate for MET immunohistochemistry (IHC). MET OE was determined using anti-MET clone SP44 IHC assay (Roche Tissue Diagnostics; positive if ≥25% cells at 3+ intensity). MET FISH, RNAseq, and whole exome sequencing were conducted. Clinical data were extracted from electronic health records, and unadjusted hazard ratios from 1L treatment initiation until death or censoring were calculated. Pts receiving targeted therapy in 1L were excluded.
Results
84 pts were included; 77% had samples taken prior to metastatic spread. 21 (25%) were MET OE positive. MET OE was not associated with history of smoking. METamp was found in 5/69 tumors evaluated (9%); of these, 2 were MET OE. Only 2 pts had MET mutations; neither were exon 14 skipping and one was MET OE. MET mRNA, evaluated in 58 cases, was 4-fold higher in MET OE NSCLC vs not OE. 1L regimens used were chemotherapy (52.4%), chemotherapy + immune checkpoint inhibitor (ICI; 26.2%), or ICI (21.4%). The unadjusted hazard ratio for death in pts with MET OE NSCLC vs not OE was 2.04 (95% CI: 1.02, 4.10).
Conclusions
Pts with MET OE NSCLC had worse prognosis compared with those without MET OE, when treated with standard of care including ICI. Given the development of MET-directed ADCs, MET OE (distinct from METamp) may be a future target for characterization and treatment of NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the abstract. All authors had access to relevant data and participated in the drafting, review, and approval of this abstract. No honoraria or payments were made for authorship.
Funding
AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the abstract. All authors had access to relevant data and participated in the drafting, review, and approval of this abstract. No honoraria or payments were made for authorship.
Disclosure
J. Bar: Financial Interests, Personal, Advisory Board: AbbVie, AstraZeneca, Bayer, BMS, Causalis, Eisai, MSD, Novartis, Roche, Takeda; Financial Interests, Personal, Research Funding: Immunai, OncoHost, MSD, AstraZeneca. M.H. Cai: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. Y.C. Choi: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. S. Baijal: Financial Interests, Personal, Other, Honoraria: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Foundation One, Gilead, GSK, Janssen, Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Pierre Fabre, Pfizer, Roche, Servier, Sanofi, and Takeda. W. Zhao: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. A. Liede: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. L. Raskin: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. A. Vasilopoulos: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. M. Li: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. L. Roberts-Rapp: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc.. F. Jiang: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. C. Ratajczak: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. S. Lu: Financial Interests, Personal, Other, Grants or contracts: AstraZeneca, Hutchmed, Bristol Myers Squibb, Hengrui Medicine, BeiGene, Roche, and Hansoh; Financial Interests, Personal, Other, Honoraria for lectures or presentations: AstraZeneca and Hansoh; Financial Interests, Personal, Other, Advisor and consultant: AstraZeneca, Pfizer, Hutchmed, Zai Lab, GenomiCare Biotechnology (Shanghai), Yuhan, Menarini, InventisBio Co., and Roche; Financial Interests, Personal, Other, Data safety monitoring board or advisory board participation: AstraZeneca, Roche, and Mirati Therapeutics. P.J. Ansell: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. D.R. Camidge: Financial Interests, Personal, Advisory Role: AbbVie (steering committee), Amgen, Anheart, Apollomics (SRC), AstraZeneca (SRC/SC), AstraZeneca/Daiichi (ILD adjudication committee), BeiGene (IDMC, DSMB), Bio-Thera (DSMB), Blueprint, Daiichi Sankyo (ILD adjudication committee), Dizal, Elevation (SRC), ; Financial Interests, Personal, Other, Company-sponsored trials at institution (PI roles): AbbVie, AstraZeneca, Blueprint, Dizal, Inhibrx, Karyopharm, Nuvalent, Pfizer, Phosplatin, PsiOxus, Rain, Roche/Genentech, Seattle Genetics, Takeda, Turning Point, Verastem.
Resources from the same session
1443P - Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI + CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3
Presenter: Miranda Gogishvili
Session: Poster session 20
1444P - Sintilimab with two cycles nab-paclitaxel / platinum as first line therapy for advanced squamous non-small-cell lung cancer: The final analysis and biomarker results
Presenter: Huijuan Wang
Session: Poster session 20
1445P - A randomized phase III trial on Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN), results of the interim analysis
Presenter: Ilias Houda
Session: Poster session 20
1447P - IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Mauricio Burotto
Session: Poster session 20
1449P - The preliminary data from a single-arm, open-label, multicenter phase II clinical trial: KN046 combined with axitinib as first-line (1L) treatment for NSCLC
Presenter: Yuanyuan Zhao
Session: Poster session 20
1450P - Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases
Presenter: Matthieu Roulleaux Dugage
Session: Poster session 20
1451P - Identifying long-term responders to immune checkpoint blockade: Potential utility of serum proteomic profiling in metastatic non-small cell lung cancer
Presenter: Rafael Bach Mora
Session: Poster session 20
1452P - Factors associated with real-world (rw) outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE
Presenter: Stephen Liu
Session: Poster session 20